Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.

Slides:



Advertisements
Similar presentations
The MADIT II Trial Multicenter Autonomic Defibrillator Implantation Trial II Presented at the American College of Cardiology 51st Annual Scientific Session.
Advertisements

EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Cardiovascular Disaster in Hemodialysis patients
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
for internal use only Evidence Based Medicine The Need to Avoid Unnecessary Ventricular Stimulation.
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Syncope Priya Victor M.D. Introduction ► Syncope is defined as transient loss of consciousness and postural tone ► Accounts for 3% of all ER visits and.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
Syncope AM Report 6/25/10 Nicole Wilde. Syncope  Cause Not Obvious Neurally Mediated (vasovagal) 58% Cardiac Disease (arrhythmias) 23% Neurologic or.
Implantable Cardioverter Defibrillator Rebecca Boduch Biomedical Engineering University of Rhode Island.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Sudden death as co-morbidity in patients following vascular intervention Sudden death as co-morbidity in patients following vascular intervention Impact.
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
SYNCOPE. 42 yo man comes to the ER with syncope He was standing in line waiting to renew his driver’s license Felt tired, nauseated, few seconds later.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
 Main Reference ◦ ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
CAROTID SINUS SYNDROME Evidence review. Introduction The hypersensitive carotid sinus syndrome (CSS) is defined as syncope or presyncope resulting from.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
EP Show – Aug 2003 ICDs – Primary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical.
Treatment of Heart Failure: Beyond Medical Therapy
Ultra long term outcomes in adult survivors of tetralogy of Fallot and the effect of pulmonary valve replacement Dobson R1,2, Danton M2, Walker N2, Tzemos,
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
Sudden Cardiac Death; Invasive Evaluation Alpay Çeliker MD Hacettepe University Department of Pediatric Cardiology Ankara, Türkiye.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical.
Syncope diagnostic algorithm and management MUDr. Jakub Honěk Kardiologická klinika, 2.LF UK a FN Motol, Praha.
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
Device and Antiarrhythmic Drugs: Advantages and Pitfalls Teresa Menendez Hood, M.D.
William M. Miles, MD, FHRS University of Florida College of Medicine Gainesville, FL ICD Implantation: Genetic Arrhythmia Syndromes.
CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop.
晕 厥 -Syncope 浙江大学医学院附属第二医院 心内科 项美香. Definition Syncope is a T-LOC (transient loss of conscious) due to transient global cerebral hypo-perfusion characterized.
The Electrical Management of Cardiac Rhythm Disorders Tachycardia Indications for ICD Implantation.
Ordering Echocardiograms for Syncope Cost Conscious Project Marvin Chang, PGY2.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
An ICD for every CRT patient ?
EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.
1 Tedisamil for Conversion of Atrial Fibrillation Thomas A. Marciniak, M.D. Division of Cardiovascular and Renal Products U.S. Food & Drug Administration.
© 2008, American Heart Association. All rights reserved. AHA/ACC/HRS Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Dr. Frank L.Y. Tam Queen Elizabeth Hospital Cardiology Division.
Consultant Cardiologist
Complex Devices..... Biventricular Pacemaker: (aka Cardiac Resynchronisation Therapy) Treats subset of patients with heart failure Needs high quality.
THE HEART’S ELECTRICAL SYSTEM Marco Perez, MD Center for Inherited Cardiovascular Disease Inherited Cardiac Arrhythmia Clinic June 20, 2013.
Transient loss of consciousness (‘blackouts’) management in adults and young people – ambulance service slide set Implementing NICE guidance August 2010.
Recurrent Syncope in Childhood 26/11/15. What is Syncope? Syncope is a temporary loss of consciousness resulting from a reversible disturbance of cerebral.
Emergency Medicine Junior Teaching Programme Aberdeen Royal Infirmary Adult Syncope Evaluation in the Emergency Department Jamie Cooper Teaching 4 th March.
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
Ethical Scenario: Cardiovascular System
Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.
Disclosures None.
Implantable Defibrillator Therapy Post Cardiac Arrest
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
Next-generation sequencing increases the diagnostic yield in aborted sudden cardiac death caused by hereditary heart disease   Brøndberg AK1, Christiansen.
Pacemakers and Implantable Cardioverter-Defibrillators
Results from the PROVIDE Trial
The most common cause of death in North America is cardiac death and the most common cause of cardiac death is sudden death from ventricular arrhythmias.
The EP show: sudden death, part 1 Director
David D. Berg et al. JACC 2018;71:
Belinda Gray et al. JCHF 2013;1:
Syncope diagnostic algorithm and management
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Presentation transcript:

Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices

Falling Man, Rodin Those who suffer from frequent and severe fainting often die suddenly Hippocrates, 1000 BC

A brief history of devices…. Seymour Furman, cardiac surgeon in New York, first demonstrated effective endocardial pacing in a patient in 1958 Pacing lead seemed most stable in the RV apex Senning and Elmquist undertook first fully implantable pacing procedure in Stockholm in 1958 Device failed within 12 hours

Moving forward 50 years…. Implantable device therapy has moved on significantly to include three main categories Pacing for bradycardia Pacing to improve cardiac function Cardiac resynchronisation therapy Implantable cardioverter defibrillators (ICDs) In addition, there are also implantable loop recorders (ILRs), also classified by the MHRA as Active Implantable Medical Devices (AIMDs)

Does age matter with devices? Is there age discrimination? Reduced number of implants Increased number of implants Do older patients respond differently? Less response to device therapy/use Greater response to device therapy/use Is syncope different in older people? Less device-relevant pathology More device-relevant therapy

Is there age discrimination? Reduced number of implants Increased number of implants

Data corrected for age and sex (except CRT) National variation in implant rates

Patient Age – All Devices, New Implants 2007 > 65 years = 84% > 70 years = 76% > 75 years = 62% > 85 years = 23%

Primary Aetiology at Implant At least 70% of aetiology likely to be age-related

New Pacemaker Implant Rates – UK Trends

New ICD Implant Rates – UK Trends

Do older patients respond differently? Less response to device therapy/use Greater response to device therapy/use Different response to device therapy/use

Time after entry to trial (years) Mortality proportion VVI VVIR DDD Hazard Ratio 95% CIp value VVI v DDD , VVIR v DDD , No differences UKPACE – All cause mortality

Hazard Ratio 95% CIp value VVI & VVIR v DDD , Time after entry to trial (years) Proportion with endpoint VVI/VVIR DDD Atrial fibrillation UKPACE - Time to specified cardiovascular events

Is syncope different in older people? Less device-relevant pathology? More device-relevant therapy?

Causes of Syncope Neurally-mediated reflex syncopal syndromes Vasovagal, carotid sinus, situational, neuralgia Orthostatic Cardiac Arrhythmias Bradycardia, tachycardia Structural Cardiac or Cardiopulmonary Disease William Stokes Robert Adams

Causes of Loss of Consciousness Data pooled from 6 population-based studies performed in the 1980’s N = 1499 patients The cause was undetermined in 35% of all cases of syncope Of those with a cardiac cause (n=245), the majority (n=195) were due to a primary arrhythmic mechanism Causes of LOC 38% 17% 10% 35% NM & Orthostatic Cardiac Neuro-psychiatric Unknown

Causes of Loss of Consciousness Data pooled from 3 referral Syncope Units in 2001 N = 342 patients The cause was undetermined in 18% of all cases of syncope Of those with a cardiac cause (n=78), the majority (n=68) were due to a primary arrhythmic mechanism Causes of LOC 58% 23% 1% 18% NM & Orthostatic Cardiac Neuro-psychiatric Unknown Alboni P et al, JACC 2001;37:1921-8

Prognostic stratification Risk stratification: age > 45 years history of congestive heart disease history of ventricular arrhythmias abnormal ECG Arrhythmias or death within one year: 4 - 7% of patients with 0 factors % in patients with  3 factors

Catching the spontaneous episode… Implantable Loop Recorder ~ £1500 Lasts ~ 12 months Patient and/or auto-activated Evidence suggests higher diagnostic rate in elderly and confused patients

Sudden Cardiac Death

Indications for ICD Indications for ICD Secondary prevention Survivors of VT/VF cardiac arrest Spontaneous VT causing syncope Sustained VT without syncope/cardiac arrest with LVEF < 35%, NYHA Class < III Primary prevention MI > 4 weeks previously and Either: LVEF < 35%, NYHA < III + Non-sustained VT on Holter + Inducible VT on EP testing Or: LVEF < 30%, NYHA < III + QRS duration > 120 msec Familial cardiac condition with risk of sudden death No mention of age!

Conclusions No clear evidence for age discrimination with regard to device use in older patients Older patients are more likely to have syncope with underlying pathology requiring pacing or ICD therapy Older patients may be less suitable for ICDs by virtue of co-existing pathology Older patients may have a higher diagnostic yield from implantable loop recorders